Publications in collaboration with researchers from Hospital Universitario Puerta de Hierro (34)

2024

  1. Recent outcomes of liver transplantation for Budd-Chiari syndrome: A study of the European Liver Transplant Registry (ELTR) and affiliated centers

    Hepatology, Vol. 80, Núm. 1, pp. 136-151

  2. Repeated pancreatic resection for pancreatic metastases from renal cell Carcinoma: A Spanish multicenter study (PANMEKID)

    Surgical Oncology, Vol. 52

  3. Textbook outcome in patients with biliary duct injury during cholecystectomy

    Journal of Gastrointestinal Surgery, Vol. 28, Núm. 5, pp. 725-730

2022

  1. Abdominal normothermic regional perfusion in controlled donation after circulatory determination of death liver transplantation: Outcomes and risk factors for graft loss

    American Journal of Transplantation, Vol. 22, Núm. 4, pp. 1169-1181

  2. Decreased Long-Term Severe Acute Respiratory Syndrome Coronavirus 2–Specific Humoral Immunity in Liver Transplantation Recipients 12 Months After Coronavirus Disease 2019

    Liver Transplantation, Vol. 28, Núm. 6, pp. 1039-1050

  3. Machine Learning-Based Analysis in the Management of Iatrogenic Bile Duct Injury During Cholecystectomy: a Nationwide Multicenter Study

    Journal of Gastrointestinal Surgery, Vol. 26, Núm. 8, pp. 1713-1723

  4. Pancreatic metastases from renal cell carcinoma. Postoperative outcome after surgical treatment in a Spanish multicenter study (PANMEKID)

    European Journal of Surgical Oncology, Vol. 48, Núm. 1, pp. 133-141

2021

  1. Corrigendum to “Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules” [J Hepatol (2019) 874–884] (Journal of Hepatology (2019) 70(5) (874–884), (S0168827819300157), (10.1016/j.jhep.2019.01.005))

    Journal of Hepatology

  2. Diagnosis and treatment of hepatocellular carcinoma. Update of the consensus document of the AEEH, AEC, SEOM, SERAM, SERVEI, and SETH

    Medicina Clinica, Vol. 156, Núm. 9, pp. 463.e1-463.e30

  3. Protective Role of Tacrolimus, Deleterious Role of Age and Comorbidities in Liver Transplant Recipients With Covid-19: Results From the ELITA/ELTR Multi-center European Study

    Gastroenterology, Vol. 160, Núm. 4, pp. 1151-1163.e3

  4. Radiological response to nivolumab in patients with hepatocellular carcinoma: A multicenter analysis of real-life practice

    European Journal of Radiology, Vol. 135

2020

  1. International and multicenter real-world study of sorafenib-treated patients with hepatocellular carcinoma under dialysis

    Liver International, Vol. 40, Núm. 6, pp. 1467-1476

2019

  1. Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules

    Journal of Hepatology, Vol. 70, Núm. 5, pp. 874-884

2018

  1. Complete response under sorafenib in patients with hepatocellular carcinoma: Relationship with dermatologic adverse events

    Hepatology, Vol. 67, Núm. 2, pp. 612-622

  2. Direct-acting antivirals are effective and safe in HCV/HIV-coinfected liver transplant recipients who experience recurrence of hepatitis C: A prospective nationwide cohort study

    American Journal of Transplantation, Vol. 18, Núm. 10, pp. 2513-2522

2017

  1. Cardiovascular morbidity and mortality after liver transplantation: The protective role of mycophenolate mofetil

    Liver Transplantation, Vol. 23, Núm. 4, pp. 498-509

  2. Clinical characteristics of hepatocellular carcinoma in Spain. Comparison with the 2008-2009 period and analysis of the causes of diagnosis out of screening programs. Analysis of 686 cases in 73 centers

    Medicina Clinica, Vol. 149, Núm. 2, pp. 61-71

  3. Effectiveness and safety of ombitasvir, paritaprevir, ritonavir ± dasabuvir ± ribavirin: An early access programme for Spanish patients with genotype 1/4 chronic hepatitis C virus infection

    Journal of Viral Hepatitis, Vol. 24, Núm. 3, pp. 226-237

  4. Efficacy and safety of daclatasvir-based antiviral therapy in hepatitis C virus recurrence after liver transplantation. Role of cirrhosis and genotype 3. A multicenter cohort study

    Transplant International, Vol. 30, Núm. 10, pp. 1041-1050

  5. Subclinical antibody-mediated rejection

    Transplantation, Vol. 101, Núm. 6, pp. S1-S18